Menu
Back to User profile » Dr Viswanathan Mohan
Papers published by Dr Viswanathan Mohan:
TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
Joshi D, GJ P, Ghosh S, Mohanan A, Joshi S, Mohan V, Chowdhury S, Dutt C, Tandon N
Diabetes, Metabolic Syndrome and Obesity 2022, 15:615-631
Published Date: 25 February 2022
Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries
Dutt C, Nunes Salles JE, Joshi S, Nair T, Chowdhury S, Mithal A, Mohan V, Kasliwal R, Sharma S, Tijssen J, Tandon N
Diabetes, Metabolic Syndrome and Obesity 2022, 15:451-465
Published Date: 16 February 2022
Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study
Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, Sethi B, Gaurav K, Patted URH, Bhagat SV, Mane AI
Diabetes, Metabolic Syndrome and Obesity 2021, 14:2925-2933
Published Date: 29 June 2021
Challenges Involved in Incorporating Personalised Treatment Plan as Routine Care of Patients with Diabetes
Unnikrishnan R, Radha V, Mohan V
Pharmacogenomics and Personalized Medicine 2021, 14:327-333
Published Date: 16 March 2021
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S
Drug Design, Development and Therapy 2020, 14:2487-2501
Published Date: 24 June 2020
Obesity – Are we continuing to play the genetic “blame game”?
Radha V, Mohan V
Advances in Genomics and Genetics 2016, 6:11-23
Published Date: 18 November 2016
Predictive value of genomics in the screening of type 2 diabetes: limitations and current status
Radha V, Mohan V
Advances in Genomics and Genetics 2014, 4:45-57
Published Date: 15 May 2014